dc.contributor.author | Machiels, J-P | |
dc.contributor.author | Tao, Y | |
dc.contributor.author | Burtness, B | |
dc.contributor.author | Tahara, M | |
dc.contributor.author | Licitra, L | |
dc.contributor.author | Rischin, D | |
dc.contributor.author | Waldron, J | |
dc.contributor.author | Simon, C | |
dc.contributor.author | Gregoire, V | |
dc.contributor.author | Harrington, K | |
dc.contributor.author | Alves, GV | |
dc.contributor.author | Figueiredo Lima, IP | |
dc.contributor.author | Pointreau, Y | |
dc.contributor.author | M Hughes, BG | |
dc.contributor.author | Aksoy, S | |
dc.contributor.author | Hetnal, M | |
dc.contributor.author | Ge, JY | |
dc.contributor.author | Brown, H | |
dc.contributor.author | Cheng, J | |
dc.contributor.author | Bidadi, B | |
dc.contributor.author | Siu, LL | |
dc.date.accessioned | 2021-03-23T12:00:51Z | |
dc.date.available | 2021-03-23T12:00:51Z | |
dc.date.issued | 2020-06-03 | |
dc.identifier.citation | Future oncology (London, England), 2020, 16 (18), pp. 1235 - 1243 | |
dc.identifier.issn | 1479-6694 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4436 | |
dc.identifier.eissn | 1744-8301 | |
dc.identifier.doi | 10.2217/fon-2020-0184 | |
dc.description.abstract | Current treatment guidelines for patients with locally advanced head and neck squamous cell carcinoma (HNSCC) recommend multimodal treatment, including chemoradiation therapy (CRT) or surgery followed by radiation, with or without chemotherapy. The immune checkpoint inhibitor pembrolizumab has previously demonstrated antitumor activity in recurrent and/or metastatic HNSCC in large Phase III trials. For patients with locally advanced disease, Phase Ib data on the use of pembrolizumab in combination with chemoradiation have shown the approach to be safe and feasible. We describe here the design and rationale for KEYNOTE-412, a randomized, double-blind, Phase III trial investigating pembrolizumab or placebo administered concurrently with CRT and as maintenance treatment in patients with locally advanced HNSCC. Clinical Trial Registration: NCT03040999 (ClinicalTrials.gov). | |
dc.format | Print-Electronic | |
dc.format.extent | 1235 - 1243 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | FUTURE MEDICINE LTD | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | |
dc.subject | Humans | |
dc.subject | Neoplasm Metastasis | |
dc.subject | Neoplasm Staging | |
dc.subject | Combined Modality Therapy | |
dc.subject | Antibodies, Monoclonal, Humanized | |
dc.subject | Chemoradiotherapy | |
dc.subject | Maintenance Chemotherapy | |
dc.subject | Antineoplastic Agents, Immunological | |
dc.subject | Squamous Cell Carcinoma of Head and Neck | |
dc.title | Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2020-04-17 | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.2217/fon-2020-0184 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | |
rioxxterms.licenseref.startdate | 2020-06-03 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Future oncology (London, England) | |
pubs.issue | 18 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy | |
pubs.publication-status | Published | |
pubs.volume | 16 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Targeted Therapy | |
icr.researchteam | Targeted Therapy | |
dc.contributor.icrauthor | Harrington, Kevin | |